Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Section 5 of 6

Economic information and modeling report

37 evidence topics · 29 sources

Modeling overview

Summary: comparator prices, payer criteria, ICER assessment, published economic evaluations, and utility weights

No price, cost-effectiveness analysis, or budget impact analysis of lanifibranor was identified. Inventiva states that market acceptance of lanifibranor “will depend significantly on the availability of coverage and adequate reimbursement from third-party payors”.

The two approved comparators for noncirrhotic MASH with F2 to F3 fibrosis have these published prices. Resmetirom (Rezdiffra) has a wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength (60, 80, and 100 mg) as of October 1, 2026, and was reported at a launch annual wholesale acquisition cost of $47,400 in March 2024. Semaglutide 2.4 mg (Wegovy) has a list price of $1,349.02 per package; Novo Nordisk announced on February 24, 2026 that the list price of Wegovy will be lowered to $675, effective January 1, 2027, a reduction of approximately 50%.

Five payer policies were reviewed (Cigna, Prime Therapeutics HCSC, Aetna, PA Health and Wellness, Alaska Medicaid). Each requires F2 or F3 fibrosis confirmed by liver biopsy or noninvasive testing, with biopsy look-back periods of 12 months to 3 years where one is stated, and Cigna, Aetna, and PA Health and Wellness require prescribing by or in consultation with a specialist. Prime Therapeutics HCSC requires an inadequate response after 72 weeks of semaglutide, or one of its listed exceptions, before resmetirom, and PA Health and Wellness requires a 6-month semaglutide trial in members without F3 fibrosis. ICER's 2023 policy recommendations state that liver biopsy should not be universally required for diagnosis and that step therapy requiring prior pioglitazone or vitamin E is not reasonable.

ICER's May 2023 assessment rated resmetirom “C++” compared with standard of care in NASH with F2 or F3 fibrosis. Its lifetime Markov model (health care sector perspective, annual cycles) used utilities of 0.76 for fibrosis stages F0 to F2 and 0.73 for F3, derived from the GAIN study, and annual costs of $7,063 and $8,423 for those states, based on US estimates from the GAIN study (2022 US dollars). At a placeholder price of $19,000 per year, resmetirom produced lifetime savings of approximately $22,400 and approximately 0.60 QALYs gained. The health-benefit price benchmark for resmetirom was $39,600 to $50,100. ICER applied a prevalence of 1.4% to US adults, assumed 762,119 treatment initiators per year, found that 6.5% of eligible patients could be treated at the placeholder price before reaching its budget impact threshold of approximately $777 million per year, and issued an access and affordability alert.

Published US cost-effectiveness analyses of the approved comparators report these incremental cost-effectiveness ratios (the first three against standard of care): semaglutide $42,200 and resmetirom $95,981 per QALY at 5 years (US payer perspective); semaglutide 2.4 mg $19,911, resmetirom 80 mg $346,810, and resmetirom 100 mg $198,607 per QALY over a lifetime (model developed under contract with Novo Nordisk); tirzepatide $42,705, semaglutide $80,076, and resmetirom $273,445 per QALY over a lifetime, using annual treatment costs of $59,268.96 for resmetirom and $16,188.24 for semaglutide; and resmetirom $53,929 per QALY in an early Madrigal-funded analysis. A cost-utility analysis of pioglitazone and vitamin E in NASH with fibrosis level 3 or greater reported $A2748 and $A8475 per QALY gained compared with lifestyle modification alone. Noninvasive-test screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis in the model, ranged from $23,265 to $27,884 per QALY.

A Madrigal-funded budget impact analysis for a hypothetical one-million-member US private plan estimated 50 to 238 patients treated with resmetirom over years 1 to 3, a net budget impact of $2.2 to $9.5 million, and $0.19 to $0.80 per member per month. A Madrigal-funded calculator estimated 1,255 to 1,699 treatment-eligible adults per 1 million commercial members in years 1 to 3, and an NHANES 2017 to March 2020 analysis estimated 8.3 million (liberal criteria) and 2.3 million (restrictive criteria) US adults meeting resmetirom eligibility criteria.

Published utility weights by fibrosis stage include mean EQ-5D indices of 0.80 (F0 to F2) and 0.67 (F3 to F4) in US respondents of the GAIN study, discrete choice experiment-derived values of 0.671 (MASH F2) and 0.605 (MASH F3) used as model inputs, and a mapped EQ-5D utility of approximately 0.78 at baseline in ESSENCE.

Payer coverage: Cigna National Formulary prior authorization criteria for resmetirom, April 2026

“Cigna National Formulary Coverage” (opens the source at this quote in a new tab)

“REVIEW DATE: 04/08/2026” (opens the source at this quote in a new tab)

“Prior Authorization is recommended for prescription benefit coverage of Rezdiffra.” (opens the source at this quote in a new tab)

“Approve for 1 year if the patient meets ONE of the following (A or B):” (opens the source at this quote in a new tab)

“Patient has stage F2 or F3 fibrosis prior to initiating treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet” (opens the source at this quote in a new tab)

“Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet” (opens the source at this quote in a new tab)

“Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet” (opens the source at this quote in a new tab)

“with a score of ≥ 9.2 to ≤ 10.5” (opens the source at this quote in a new tab)

“The medication is prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist” (opens the source at this quote in a new tab)

“Patient has completed ≥ 1 year of therapy with Rezdiffra AND according to the prescriber, the patient has not had worsening of fibrosis or MASH/NASH” (opens the source at this quote in a new tab)

ICER coverage policy recommendations for NASH therapies, May 2023

ICER potential budget impact: eligible US adults, uptake, and access and affordability alert

Published cost-effectiveness analysis: semaglutide 2.4 mg and resmetirom compared with standard of care, US third-party payer perspective, lifetime horizon, Novo Nordisk-funded

“Cost effectiveness was assessed from a United States (US) third-party payer perspective. The impact of semaglutide 2.4 mg on quality-adjusted life years (QALYs), cost, and clinical outcomes was simulated over a lifetime horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Costs were adjusted to 2025 US dollars. Costs and health outcomes were discounted at 3% annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the cost-effectiveness analysis, semaglutide 2.4 mg had an incremental cost-effectiveness ratio of US$19,911 per QALY gained compared with SoC, while corresponding incremental cost-effectiveness ratios were US$346,810 for resmetirom 80 mg and US$198,607 for resmetirom 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a scenario analysis that used the direct-to-consumer cash price for semaglutide 2.4 mg (US$499 per month), semaglutide 2.4 mg was less costly and more effective than SoC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These utilities were taken from the Institute for Clinical and Economic Review 2023 NASH assessment, which sourced fibrosis stage values from the GAIN study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“FC is an employee of Genesis Research Group (Hoboken, NJ), which was contracted by Novo Nordisk Inc., Plainsboro, NJ, USA to develop the model and manuscript.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Published cost-effectiveness analysis: resmetirom, semaglutide, and tirzepatide compared with standard of care in MASH with F2 to F3 fibrosis, US payer perspective, lifetime horizon, with model inputs

Model inputBase caseRange
Annual treatment cost ($), resmetirom“59268.96”View highlighted excerpt for this quote“(47415.17, 71122.75)”View highlighted excerpt for this quote
Annual treatment cost ($), semaglutide“16188.24”View highlighted excerpt for this quote“(12950.59, 19425.89)”View highlighted excerpt for this quote
Annual treatment cost ($), tirzepatide“13036.44”View highlighted excerpt for this quote“(10429.15, 15643.73)”View highlighted excerpt for this quote
Annual health state cost ($), MASH F2“512.94”View highlighted excerpt for this quote“(410.35, 615.53)”View highlighted excerpt for this quote
Annual health state cost ($), MASH F3“631.39”View highlighted excerpt for this quote“(505.11, 757.67)”View highlighted excerpt for this quote
Annual health state cost ($), F4“22501.38”View highlighted excerpt for this quote“(18001.1, 27001.66)”View highlighted excerpt for this quote
Utility, MASH F2“0.671”View highlighted excerpt for this quote“(0.607, 0.736)”View highlighted excerpt for this quote
Utility, MASH F3“0.605”View highlighted excerpt for this quote“(0.591, 0.620)”View highlighted excerpt for this quote
Utility, MASH F4“0.500”View highlighted excerpt for this quote“(0.478, 0.523)”View highlighted excerpt for this quote
Utility, decompensated cirrhosis“0.251”View highlighted excerpt for this quote“(0.204, 0.299)”View highlighted excerpt for this quote

Budget impact analysis: resmetirom in a hypothetical one-million-member US private health plan over 3 years, Madrigal-funded

“A three-year budget impact analysis based on an open cohort state transition model was developed for a hypothetical one-million-member private health plan.” (opens the source at this quote in a new tab)

“from a US private payer perspective.” (opens the source at this quote in a new tab)

“The resmetirom price was based on its March 2024 wholesale acquisition cost (WAC)” (opens the source at this quote in a new tab)

“In the projected scenario case where resmetirom is covered in a one-million-member private payer, 50, 117, and 238 patients were treated with resmetirom in each of the first 3 years.” (opens the source at this quote in a new tab)

“Compared with a scenario without resmetirom, the introduction of resmetirom yielded results ranging from 50 to 238 treated patients, net budget impact of $2.2 to $9.5 million, and PMPM from $0.19 to $0.80 over years one and three.” (opens the source at this quote in a new tab)

“the model operated under the assumption that 4%, 8%, and 14% of treatment-eligible patients would receive resmetirom in the first three years of the projected scenario.” (opens the source at this quote in a new tab)

“Market shares are based on internal forecasts, a short time horizon, average treatment effects, and other limitations common to BIMs.” (opens the source at this quote in a new tab)

“Design, study conduct, and financial support for the study were provided by Madrigal Pharmaceuticals, Inc.” (opens the source at this quote in a new tab)

Eligible population per 1 million US commercial members: diagnosed adults with noncirrhotic NASH and F2 to F3 fibrosis, Madrigal-funded calculator

Health-state utility weights: EQ-5D by early (F0 to F2) and advanced (F3 to F4) fibrosis in biopsy-confirmed NASH, GAIN study, Europe and the United States

Lanifibranor price, cost-effectiveness analysis, or budget impact analysis

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.